BTK Inhibitor Ring Derivatives for Bioavailability and Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for BTK-related diseases such as tumors and autoimmune disorders lack effective BTK inhibitors with high bioavailability and safety.
Innovation Solution
Development of a novel BTK inhibitor compound represented by general formula (I) or its stereoisomers, pharmaceutically acceptable salts, or co-crystals, which utilize a PROTAC technology to target BTK for degradation, enhancing efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional BTK inhibitors are used, then BTK activity is inhibited, but bioavailability and safety are insufficient
Solution Approach 1:
The patent modifies the molecular structure of BTK inhibitors by changing chemical parameters (introducing specific heterocyclic rings, adjusting substituent groups, optimizing molecular weight and logP values) to improve both efficacy and safety profiles. The compound of formula (I) incorporates specific structural modifications that enhance binding affinity while reducing off-target effects.
Solution Approach 2:
The invention creates a composite molecular structure combining multiple functional moieties: a BTK-binding core structure with specific heterocyclic groups (pyrimidine, pyridine, triazine rings) and hydrophilic/hydrophobic substituents. This composite approach allows simultaneous optimization of potency and safety by integrating multiple functional elements in a single molecule.
2Reliability
If conventional BTK inhibitors are used, then BTK activity is inhibited, but bioavailability is insufficient
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by adjusting molecular properties such as molecular weight (150-300 Da), logP values (0.5-3.0), and hydrogen bonding capabilities. These parameter changes enhance membrane permeability and metabolic stability, thereby improving bioavailability while maintaining efficacy.
Solution Approach 2:
The invention introduces specific local structural features at key positions in the molecule: hydrophilic groups (carboxyl, hydroxyl, amino) at certain positions and hydrophobic groups (aromatic rings, aliphatic chains) at others. This local quality differentiation optimizes both binding affinity and absorption characteristics.
3Reliability
If PROTAC technology is applied to target BTK for degradation, then BTK is degraded, but compound complexity increases
Solution Approach 1:
The patent divides the PROTAC compound into distinct functional segments: a BTK-binding ligand portion, a linker portion, and an E3 ubiquitin ligase binder portion. This segmentation allows independent optimization of each module while maintaining overall functionality, reducing the complexity burden despite the dual-function requirement.
Solution Approach 2:
The invention employs a carefully designed linker as an intermediary element that connects the BTK-binding and E3 ligase-binding moieties. This intermediary component facilitates the PROTAC mechanism while minimizing steric hindrance and molecular complexity, enabling effective BTK degradation through a manageable structural architecture.
Data Source
AI summary
A BTK inhibitor ring derivative, a preparation method therefor and a pharmaceutical application thereof. The BTK inhibitor ring derivative is a compound represented by a general formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or co-crystal thereof, and the BTK inhibitor ring derivative is used to treat BTK-related diseases such as tumors or autoimmune system diseases.